From SNPedia
| Geno
|
Mag
|
Summary
|
| (C;C)
|
1.2
|
one of 2 snps relevant to classifying APOE genotype
|
| (C;T)
|
|
>3x increased risk for Alzheimer's; 1.4x increased risk for heart disease
|
| (T;T)
|
0
|
common
|
| ? | (C;C) (C;T) (T;T) | 28 |
 |
This SNP, located in the fourth exon of the ApoE gene, affects the amino acid at position 130 of the resulting protein. The more common rs429358 allele is (T). If the allele is (C) and the same chromosome also harbors the rs7412(C) allele, the combination is known as an ApoE4 allele. The ApoE4 allele has a strong influence on the risk of Alzheimer's disease. Both deCODEme and 23andMe (v3 chip) test for this SNP.
Many studies have estimated the level of risk, and it varies depending on age, sex, ethnicity, and other factors. One meta-analysis estimated the odds ratios for homozygous rs429358(C;C) individuals compared to the more common ApoE3/ApoE3 homozygotes to be 12x for late-onset Alzheimer's and 61x for early-onset disease. [PMID 10325447]
Meta-analyses have also supported the association between the ApoE4 allele and somewhat increased risk for heart disease, with an odds ratio of 1.42 (CI: 1.26 - 1.61).[PMID 15488874]
Note: Although ApoE status is technically defined by these two SNPs, rs429358 and rs7412, a SNP in the adjacent ApoC1 gene, rs4420638, is co-inherited with ApoE and thus often - though not completely - predictive of it.
| OMIM | 107741 |
| Desc | HYPERLIPOPROTEINEMIA, TYPE III, ASSOCIATED WITH APOE4 |
| Variant | 0022 |
| Related | also |
| Venter snp
|
| Source
|
plos
|
| Gene
|
APOE
|
| allele
|
C
|
| frequency
|
|
| sift
|
TOLERATED
|
| HuRef
|
1103691153316
|
| Disease Association
|
The APOE*4 allele is associated with late onset Alzheimer disease 2 (AD2) (MIM:104310). The APOE*4 allele is genetically associated with the common late onset familial and sporadic forms of Alzheimer disease (AD). Risk for AD increased from 20% to 90% and mean age at onset decreased from 84 to 68 years with increasing number of APOE*4 alleles in 42 families with late onset AD. Thus APOE*4 gene dose is a major risk factor for late onset AD and, in these families, homozygosity for APOE*4 was virtually sufficient to cause AD by age 80. The mechanism by which APOE*4 participates in pathogenesis is not known.
|
[PMID 19818961] Apolipoprotein E genotype is associated with serum C-reactive protein but not abdominal aortic aneurysm
| PharmGKB | PA165109610 |
| Name | APOE: Cys112Arg (g.7903T>C, c.388T>C, p.Cys130Arg in dbSNP build 130) |
| Annotation | Risk or phenotype-associated allele: The ApoE E2 allele is a combination of rs429358 T (130Cys) and rs7412 T (176Cys). Phenotype: The Apo E2 allele contributes to increased risk of type III hyperlipoproteinemia, characterized by increased cholesterol and triglyceride levels, the presence of beta-VLDL (cholesterol-enriched remnants of intestinal chylomicrons and hepatic VLDL), xanthomas, and premature vascular disease, both coronary heart disease and peripheral artery disease. Study size: Three multiplex, multigenerational pedigrees, and case control study of 5 probands versus 94 controls. Study population/ethnicity: Germans. Significance metric(s): N/A. Type of association: CO; GN |
| Gene | APOE, APOC1 |
| Featue | |
| Evidence | PubMed ID:199847 |
| Drugs | |
| Diseases | Arteriosclerosis, Hyperlipoproteinemia Type III, Hyperlipoproteinemias, Vascular Diseases |
| Curation Level | Curated |
| GWAS snp
|
| PMID
|
[PMID 20100581]
|
| Trait
|
Brain imaging
|
| Title
|
Whole Genome Association Study of Brain-Wide Imaging Phenotypes for Identifying Quantitative Trait Loci in MCI and AD: A Study of the ADNI Cohort
|
| Risk Allele
|
|
| P-val
|
NS
|
| Odds Ratio
|
None None
|
[PMID 20406466] Genetic variants associated with fasting blood lipids in the U.S. population: Third National Health and Nutrition Examination Survey
[PMID 20429872] Additive effects of LPL, APOA5 and APOE variant combinations on triglyceride levels and hypertriglyceridemia: results of the ICARIA genetic sub-study
[PMID 20822524] Isoform of APOE with retained intron 3; quantitation and identification of an associated single nucleotide polymorphism
[PMID 20946940] Association of variants within APOE; SORL1; RUNX1; BACE1 and ALDH18A1 with dementia in Alzheimer's disease in subjects with Down syndrome
| PharmGKB | PA162355841 |
| Name | APOE: 3937T>C, p.Cys112Arg, (g.7903T>C, c.388T>C, p.Cys130Arg in dbSNP build 130) |
| Annotation | Risk or phenotype-associated allele: ApoE E4 allele (rs429358 C, rs7412 C) (130Arg, 176Arg). Phenotype: Increased incidence of chronic plaque psoriasis and guttate psoriasis, but no difference in response of psoriasis to the drug acitretin. Study size: 306 cases, 137 controls. Study population/ethnicity: Patients with chronic plaque psoriasis (n = 212), guttate psoriasis (n = 94). Significance metric(s): p =0.008 Type of association: CO; GN |
| Gene | APOE, APOC1 |
| Featue | |
| Evidence | PubMed ID:16433808 |
| Drugs | acitretin |
| Diseases | Psoriasis |
| Curation Level | Curated |
| PharmGKB | PA162360000 |
| Name | APOE:Cys112Arg, 2060T>C, ApoE epsilon 4 |
| Annotation | The ApoE epsilon4 variant (2060C) is associated with hyperlipidemia (elevated triglyceride levels) in HIV-infected individuals treated with ritonavir. |
| Gene | APOE, APOC1 |
| Featue | |
| Evidence | PubMed ID:15809899; PubMed ID:16417409; PubMed ID:17700364 |
| Drugs | ritonavir |
| Diseases | HIV, HIV Infections, Hyperlipidemias |
| Curation Level | Curated |
| PharmGKB | PA165110264 |
| Name | APOE: epsilon3, defined as rs429358 T 130Cys + rs7412 C 176Arg |
| Annotation | Risk or phenotype-associated allele: APOE: epsilon3/epsilon3 (defined as rs429358 T/T 130Cys/Cys + rs7412 C/C 176Arg/Arg). Phenotype: Neurodegenerative disease characterized by asymmetric parietal atrophy, visuospatial dysfunction, incomplete Balint's syndrome, environmental agnosia, left-sided motor symptoms including dystonic postures and myoclonus in the left hand, without significant dementia (as in posterior cortical atrophy) was observed in a woman with early-onset neurodegenerative disease progressing 10 years from onset at age 52 to death. Study size: 1. Study population/ethnicity: Right-handed female/Japanese. Significance metric(s): non significant case report. Type of association: CO; GN |
| Gene | APOE, APOC1 |
| Featue | |
| Evidence | PubMed ID:9804125 |
| Drugs | |
| Diseases | Neurodegenerative Diseases, Posterior Cortical Atrophy |
| Curation Level | Curated |
| PharmGKB | PA165109612 |
| Name | APOE: Cys112Arg (g.7903T>C, c.388T>C, p.Cys130Arg in dbSNP build 130) |
| Annotation | Risk or phenotype-associated allele: The ApoE E4 allele is a combination of rs429358 C (130Arg) and rs7412 C (176Arg). Phenotype: The Apo E4 allele is associated with 80 percent increased risk of dying (mortality risk ratio = 1.8) compared with other patients upon evaluation at 5.5 years following survival of myocardial infarction. ApoE E4 carriers who had high Lp(a) levels had a risk ratio of 3.7 of coronary death. Simvastatin treatment reduced the mortality risk to 0.33 in Apoe E4 carriers and to 0.66 in other patients (p = 0.23 for treatment by genotype interaction). Study size: 966 survivors of myocardial infarction enrolled in the Scandinavian Simvastatin Survival Study. Study population/ethnicity: Danish and Finnish. Significance metric(s): mortality risk ratio = 1.8. Type of association: CO; PD; GN |
| Gene | APOE, APOC1 |
| Featue | |
| Evidence | PubMed ID:10736278 |
| Drugs | simvastatin |
| Diseases | Infarction, Myocardial Infarction |
| Curation Level | Curated |
| PharmGKB | PA165109614 |
| Name | APOE: Cys112Arg (g.7903T>C, c.388T>C, p.Cys130Arg in dbSNP build 130) |
| Annotation | Risk or phenotype-associated allele: The APOE E4 allele is a combination of rs429358 C (130Arg) and rs7412 C (176Arg). Phenotype: The APOE E4 allele (130Arg, 176Arg) was studied relative to the E3 (130Cys, 176Arg) and E2 (130Cys, 176Cys) alleles. Relative to the homozygous E3/E3 diplotype, Caucasians showed increased risk of Alzheimer Disease (AD): OR = 2.6 for E4/E2, OR = 3.2 for E4/E3, OR = 14.9 for E4/E4. The E2 allele was protective against risk of AD: OR = 0.6 for E2/E2, OR = 0.6 for E3/E2. Japanese showed greater increased risk of AD than Caucasians: OR=5.6 for E3/E4, OR = 33.1 for E4/E4. Study size: 5930 patients who met criteria for probable or definite AD, and 8607 controls without dementia. Study population/ethnicity: A clinic-/autopsy-based case-control study of patients between 40 and 90 years old recruited from clinical, community, and brain bank sources./Caucasian, African American, Hispanic, Japanese. Significance metric(s): OR. Type of association: CO; GN |
| Gene | APOE, APOC1 |
| Featue | |
| Evidence | PubMed ID:9343467 |
| Drugs | |
| Diseases | Alzheimer Disease |
| Curation Level | Curated |
| PharmGKB | PA165109616 |
| Name | APOE: Cys112Arg (g.7903T>C, c.388T>C, p.Cys130Arg in dbSNP build 130) |
| Annotation | Risk or phenotype-associated allele: The E3 and E4 alleles of APOE, defined by the combined genotype at rs429358T>C (Cys130Arg) and rs7412C>T (Arg176Cys). Phenotype: The APOE E3 allele (130Cys, 176Arg) and E4 (130Arg, 176Arg) alleles were protective. Carriers of the E3 allele had significantly higher average macular thickness in both eyes (p = 0.012), and significantly better visual acuity (p = 0.041) than non-E3 carriers. E4 carriers showed reduced incidence of cataract than non-APOE4 carriers (p = 0.039). Study size: 32 patients who underwent cataract surgery in both eyes, and 56 controls. Study population/ethnicity: Patients from London, England aged 50-75 years old. Significance metric(s): p-value. Type of association: CO; GN |
| Gene | APOE, APOC1 |
| Featue | |
| Evidence | PubMed ID:18498549 |
| Drugs | |
| Diseases | Cataract, Macular Degeneration |
| Curation Level | Curated |
[PMID 21263195] An APOE Haplotype Associated with Decreased ?4 Expression Increases the Risk of Late Onset Alzheimer's Disease
| GWAS snp
|
| PMID
|
[PMID 21123754]
|
| Trait
|
|
| Title
|
Genome-wide association study of CSF biomarkers A{beta}1-42, t-tau, and p-tau181p in the ADNI cohort.
|
| Risk Allele
|
|
| P-val
|
0.000001
|
| Odds Ratio
|
None None
|
[PMID 22174202] Apolipoprotein E Gene Polymorphisms Are Strong Predictors of Inflammation and Dyslipidemia in Rheumatoid Arthritis